Zobrazeno 1 - 10
of 191
pro vyhledávání: '"Matthew R. Sydes"'
Autor:
Ruth E Langley, David P. Dearnaley, H. Rush, Silke Gillessen, Mahesh K. B. Parmar, Andrew Protheroe, Robin Millman, Shaun Tolan, Zaf Malik, Peter Hoskin, Christopher D. Brawley, Duncan C. Gilbert, Simon Chowdhury, Noel W. Clarke, Sarah Rudman, Nicholas D. James, Carla Perna, Neil McPhail, J. Martin Russell, Robert Jones, John Wagstaff, Adrian Cook, Gerhardt Attard, Joanna Gale, Salil Vengalil, Emma Gray, Alison Birtle, David Gareth Fackrell, Jacob Tanguay, Matthew R. Sydes, Archie Macnair, Joe M. O'Sullivan, Chris Parker, Alicia K. Morgans, Laura Murphy, David Matheson, C. Pugh
Publikováno v:
J Clin Oncol
PURPOSE Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Th
Autor:
Sarah L. Gulliford, Emma Hall, Allison Steigler, James W. Denham, Jason Dowling, Michael G Jameson, D. Roach, David Joseph, Peter B. Greer, Angel Kennedy, David P. Dearnaley, Marco Marcello, Annette Haworth, Lois Holloway, Matthew R. Sydes, Martin A. Ebert
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:1304-1318
Purpose Reducing margins during treatment planning to decrease dose to healthy organs surrounding the prostate can risk inadequate treatment of subclinical disease. This study aimed to investigate whether lack of dose to subclinical disease is associ
Autor:
Alison Parry-Jones, F.C. Ingleby, Mahesh K. B. Parmar, Rosalind A. Eeles, Claire Amos, Zsofia Kote-Jarai, Noel W. Clarke, Nafisah B. Atako, Matthew R. Sydes, Andrea Loehr, Chris Wanstall, Clare Gilson, Duncan C. Gilbert, Alex Hoyle, Simon Chowdhury, Christopher D. Brawley, Marina Parry, Nicholas D. James, Malcolm David Mason, Melissa Gannon, Adnan Ali, Ruth E Langley, Gerhardt Attard, Andrew Simmons, Zafar Malik
Publikováno v:
JCO Precision Oncology. :882-897
PURPOSEThe STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tum
Autor:
Claire L Vale, Sylvie Chabaud, Matthew R. Sydes, Andrew Kneebone, Mahesh K. B. Parmar, Paul Sargos, Carol Fraser-Browne, Chris Brown, David Fisher, Adrian Cook, Silvia Forcat, Chris Parker, Maria Pearse, Pierre Richaud, Meryem Brihoum, Christopher D. Brawley, Igor Latorzeff, Jayne F. Tierney
Publikováno v:
The Lancet. 396:1422-1431
Summary Background It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively plan a systematic re
Autor:
Mack Roach, Stefano Fanti, Aurelius Omlin, Piet Ost, Neal D. Shore, Susan Halabi, Tomasz M. Beer, Charles G. Drake, Mark A. Rubin, Alberto Bossi, Eleni Efstathiou, Nicolas James, Christopher Sweeney, Eric J. Small, Bertrand Tombal, Apccc expert panel, Silke Gillessen, Anwar R. Padhani, Oliver Sartor, Nicolas Mottet, Karim Fizazi, Matthew R. Smith, Ursula M Vogl, Johann S. de Bono, Ian D. Davis, Gerhardt Attard, Matthew R. Sydes, Howard R. Soule
Background:Innovations in treatments, imaging and molecular characterisationhave improved outcomes for people with advanced prostate cancer; however, many aspectsof clinical management are devoid of high-level evidence. At the Advanced Prostate Cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce11600e2ef725e880da37bccc0cb67f
Autor:
Sharon B. Love, Christiane Pauli-Magnus, Patricia Arnaiz Jimenez, Marie Mi Bonde, Nicole Bruni, Matthias Briel, Pascal Benkert, Matthew R. Sydes, Hannah Ewald, Katharina Klatte
Publikováno v:
Cochrane Database Syst Rev
BACKGROUND: Trial monitoring is an important component of good clinical practice to ensure the safety and rights of study participants, confidentiality of personal information, and quality of data. However, the effectiveness of various existing monit
Autor:
Noel W. Clarke, Claire Amos, Hassan Douis, Nicholas D. James, Gerhardt Attard, Malcolm David Mason, Mahesh K. B. Parmar, Adrian Cook, Chris Parker, Alex Hoyle, J. Calvert, Christopher D. Brawley, Adnan Ali, Matthew R. Sydes
Publikováno v:
Ali, A, Hoyle, A, Parker, C C, Brawley, C D, Cook, A, Amos, C, Calvert, J, Douis, H, Mason, M D, Attard, G, Parmar, M K B, Sydes, M R, James, N D & Clarke, N 2020, ' The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer : An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison” ', European Urology Oncology . https://doi.org/10.1016/j.euo.2020.05.003
European Urology Oncology
European Urology Oncology
Background Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state is based on manual bone metastasis counts, but enumeration of bone me
Autor:
Carlos Diaz-Montana, Nurulamin M Noor, Meredith Martyn, Victoria Yorke-Edwards, Archie Macnair, Graham Powell, Sarah Lensen, Sharon B. Love, James R. Carpenter, Matthew R. Sydes, Elizabeth A. Williamson, Alexandra Blenkinsop
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-11 (2020)
Trials
Trials
Background Clinical trials generally each collect their own data despite routinely collected health data (RCHD) increasing in quality and breadth. Our aim is to quantify UK-based randomised controlled trials (RCTs) accessing RCHD for participant data
Autor:
Charles G. Drake, Matthew R. Smith, Almudena Zapatero, Charles J. Ryan, Philip W. Kantoff, Piet Ost, Inge M. van Oort, Ian D. Davis, Nicolas James, Matthew R. Sydes, Vedang Murthy, Martin E. Gleave, Maha Hussain, Michael S Hofman, Susan Halabi, Ignacio Duran, Oliver Sartor, Raya Leibowitz, Christopher P. Evans, Anders Bjartell, Ros Eeles, Mack Roach, Hiroyoshi Suzuki, Colin C. Pritchard, Levent Türkeri, Daniel Heinrich, Fred Saad, William Oh, Karim Fizazi, Himisha Beltran, Declan G. Murphy, Joe M. O'Sullivan, Thomas Steuber, Raja B. Khauli, Axel Heidenreich, Silke Gillessen, Eric J. Small, Robert E. Reiter, Juan Pablo Sade, Chris Logothetis, Tomasz M. Beer, Alberto Briganti, Mary-Ellen Taplin, Johann S. de Bono, Howard I. Scher, Eleni Efstathiou, Stefano Fanti, Darren M.C. Poon, Felix Y. Feng, Aurelius Omlin, Hind Mrabti, Chris Parker, Anwar R. Padhani, Kim N. Chi, Mark A. Rubin, Neal D. Shore, Nicolas Mottet, Alicia K. Morgans, Christopher Sweeney, Mark Frydenberg, Robert G. Bristow, Fernando C. Maluf, Robin Millman, Cora N. Sternberg, Ravindran Kanesvaran, Michael J. Morris, Noel W. Clarke, Gerhardt Attard, Alberto Bossi, Bertrand Tombal, Celestia S. Higano, Howard R. Soule
Publikováno v:
EUROPEAN UROLOGY
European Urology, Vol. 77, no. 4, p. 508-547 (2020)
European Urology, 77, 508-547
European urology, vol 77, iss 4
European Urology, 77, 4, pp. 508-547
European Urology, Vol. 77, no. 4, p. 508-547 (2020)
European Urology, 77, 508-547
European urology, vol 77, iss 4
European Urology, 77, 4, pp. 508-547
Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced
Autor:
Malcolm David Mason, Martin J. Russell, Daniel M. Aebersold, Mahesh K. B. Parmar, Clare Gilson, David Matheson, Simon Chowdhury, Robert Jones, Silke Gillessen, William Cross, Hassan Douis, Adnan Ali, Alex Hoyle, Gerhardt Attard, A.W.S. Ritchie, Christopher D. Brawley, Johann S. de Bono, Chris Parker, David P. Dearnaley, Fiona C. Ingleby, Noel W. Clarke, Adrian Cook, Matthew R. Sydes, Nicholas D. James, Robin Millman
Publikováno v:
European Urology. 76:719-728
Background Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naive prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains u